Shows
Osler Legal OutlookThe impact of stronger drug dosing patents on Canadian drug accessIn this article — "The impact of stronger drug dosing patents on Canadian drug access" — we discuss the importance of an effective balance between patent enforceability and timely access to affordable generic drugs if prescription drug costs are to be better managed. Recent jurisprudence suggests this balance may be shifting away from affordable alternatives. Further developments on this front are expected in the coming year.This article is authored by J. Bradley White, partner and Co-Chair, Intellectual Property practice along with Nathaniel Lipkus, partner and Leah McGurn, an associate both also with Osler’s Intellectual Property practice.Osler...
2024-12-0511 min
Legal Year in ReviewTime to talk about ownership of AI-generated intellectual property assetsIn this article – “Time to talk about ownership of AI-generated intellectual property assets” – we discuss how, as computers have become more powerful and they acquire higher-order brain function through machine-learning, they have developed the capacity for activity that humans would otherwise consider original or inventive, creating works worthy of copyright protection and inventions worthy of patents. In 2021, the first global court decisions grappled with whether a non-human can be an inventor for the purposes of patent law. By reviewing some of the decisions from courts around the world, we explore whether a non-human can be an inventor for the purposes...
2021-12-1710 min
Legal Year in Review2020: A year of clarity for Canadian life sciences and software patentsIn this article, “2020: A year of clarity for Canadian life sciences and software patents,” we discuss how guidance from the courts’ recent patent decisions should shape companies’ Canadian patent strategies, both during the pandemic and beyond. Amid the COVID-19 pandemic, many of the most important innovations have arisen in the life sciences and software fields, from new disease test kits and anti-viral medicines to software that enables socially distant connectivity. The past year provided clarity regarding when innovations in these fields merit patent protection and how patent litigation is likely to unfold. This article is authored by J. Bradle...
2020-12-0809 min
The Pharma PodcastCOVID-19 Special Edition – Canadian Access to Future Coronovirus Treatment – Canadian Regulatory FrameworkIn this episode I spoke with Nathaniel Lipkus, intellectual property litigator, and partner at Osler, Hoskin & Harcourt LLP.Nate is a legal expert on patent and regulatory issues facing pharmaceutical and biotechnology companies. Nate has also published extensively on topics pertaining to Canada’s Patent Act . Nate recently wrote an article for the Globe and Mail exploring today’s topic. In this episode, Nate provides insight on Canada's regulatory framework and how it can assist Canadian access to new therapeutics to the novel coronavirus. Specifically, we explore the COVID-19 Emergency Response Act (Bill C-13) and...
2020-04-2731 min